RxDoctor Payments DataLook up a doctor →

Luis Castillo, MD

Family Medicine · Palm Springs, FLNPI 1821233966

Payments from drug & device makers

$5,975,519in general payments, 2019–2025

Across 334 payments — averaging $17,891 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • BD$3.9M
  • Novartis$1.2M
  • GSK$424K
  • Pfizer$208K
  • Orasure Technologies Inc.$120K
  • Regeneron$67K
  • plus $36K from 11 others

What the payments were for

  • Food & beverage$459100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,975,519 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$136,479
Medicare patients
179
Services billed
1,948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin164$187,135
OzempicSemaglutide122$116,400
EliquisApixaban108$112,188
Breo ElliptaFluticasone/Vilanterol133$67,469
LinzessLinaclotide50$57,872
MounjaroTirzepatide50$53,304
TradjentaLinagliptin38$50,020
JanuviaSitagliptin Phosphate35$35,733
XareltoRivaroxaban21$26,345
FarxigaDapagliflozin Propanediol14$21,436
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$15,456
VascepaIcosapent Ethyl28$12,771
TrulicityDulaglutide11$10,346
Repatha SyringeEvolocumab11$9,202
SymbicortBudesonide/Formoterol Fumarate30$8,788

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$32$116,400122 claims
PfizerEliquis$208,487$112,188108 claims
GSKBreo Ellipta, Trelegy Ellipta, Shingrix$423,844$86,013171 claims
Lilly USA, LLCMounjaro, Trulicity$150$63,65161 claims
MerckJanuvia$500$35,73335 claims
AstraZenecaFarxiga, Symbicort$25$30,22344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Palm Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →